Prescient Therapeutics Ltd has released a press release.
PTX-200 AML Trial Progresses to Higher Dose
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- December 2020 Quarterly Update and Appendix 4C
- PTX announces 3 next-gen CAR-T programs with OmniCAR
- Prescient Receives $1.03m R&D Tax Rebate
- September 2020 Quarterly Update and Appendix 4C
- Response to ASX Query
Later from Prescient Therapeutics
- March 2021 Quarterly Update and Appendix 4C
- PTX signs CAR-T agreement with Peter MacCallum
- Response to ASX Price Query
- PTX Completes CAR-T Manufacturing Milestone for OmniCAR
- PTX successful immunogenicity testing of OmniCAR
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics